| 12.345 0.135 (1.11%) | 10-23 11:53 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.45  |
1-year : | 16.88 |
| Resists | First : | 12.38 |
Second : | 14.45 |
| Pivot price | 10.18 |
|||
| Supports | First : | 8.96 |
Second : | 6.86 |
| MAs | MA(5) : | 12.17 |
MA(20) : | 9.49 |
| MA(100) : | 7.07 |
MA(250) : | 7.21 |
|
| MACD | MACD : | 1.3 |
Signal : | 1 |
| %K %D | K(14,3) : | 98.8 |
D(3) : | 98.5 |
| RSI | RSI(14): 84.7 |
|||
| 52-week | High : | 12.51 | Low : | 3.55 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ATXS ] has closed below upper band by 23.1%. Bollinger Bands are 367% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 12.31 - 12.36 | 12.36 - 12.41 |
| Low: | 12.02 - 12.08 | 12.08 - 12.14 |
| Close: | 12.12 - 12.21 | 12.21 - 12.29 |
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Wed, 15 Oct 2025
Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX - Yahoo Finance
Wed, 15 Oct 2025
Astria Therapeutics: Pipeline And Market Potential Post BioCryst Acquisition - Seeking Alpha
Wed, 15 Oct 2025
Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Tue, 14 Oct 2025
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Astria Therapeutics, Inc. (NASDAQ: ATXS) - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 56 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 102.5 (%) |
| Shares Short | 3,110 (K) |
| Shares Short P.Month | 2,790 (K) |
| EPS | -2.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.93 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -25.3 % |
| Return on Equity (ttm) | -38.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -115 (M) |
| Levered Free Cash Flow | -72 (M) |
| PE Ratio | -6.13 |
| PEG Ratio | 0 |
| Price to Book value | 4.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|